Novavax Inc. Stock

Vaccine maker Novavax (NASDAQ: NVAX) is having a good year. In May, the company announced a lucrative partnership with French biotech giant Sanofi (NASDAQ: SNY), sending its stock price soaring

Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine for COVID-19. Ultimately, it did produce an approved vaccine, but it was a bit

It's been a great year for Novavax (NASDAQ: NVAX). The biotech is up by 150% since January. However, analysts see even more upside for the vaccine maker. The consensus estimate of $20 a share

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in

What a difference a few months make. Vaccine specialist Novavax (NASDAQ: NVAX) started the year poorly, continuing with the issues it has encountered since mid-2021.

Those headwinds included the

Novavax (NASDAQ: NVAX) stock is suddenly a buy again this year, with its stock price more than tripling since the start of 2024. Some positive developments in recent months, including a deal with

The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful

Novavax (NASDAQ: NVAX) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock

Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax

Novavax (NASDAQ: NVAX) has been a highly volatile stock in recent years, and that volatility is on full display again this month. Shares of the healthcare stock are up 200% since the start of May

If you'd invested $10,000 in Novavax (NASDAQ: NVAX) a year ago, you would have made a risky bet. That's because the biotech company had issued a going concern earlier this year. This warning meant

Novavax (NASDAQ: NVAX) took a turn in the investor spotlight in early May, when the vaccine specialist announced -- on the same day it unveiled its first-quarter results -- a collaboration deal with

Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this

After losing more than 90% of its value from a peak back in 2021, Novavax (NASDAQ: NVAX) stock has finally taken off. The biotech soared 190% in two trading sessions after announcing a $1.2 billion

Shares of the struggling vaccine developer Novavax (NASDAQ: NVAX) bounded 98.7% higher on Friday, May 10. The market was responding to terrific news from Sanofi (NASDAQ: SNY), a global

Shares of Novavax (NASDAQ: NVAX) are up 12% as of midday Friday following the release of the drugmaker's first-quarter results. It's not the report, however, driving the bulk of today's oversize

The market isn't rational always and everywhere. Sometimes, shares of excellent companies with bright futures almost inexplicably fail to keep pace with broader equities. When that happens, it's

If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop

In just the past 12 months, Novavax (NASDAQ: NVAX) stock has plummeted 48% in value. The once-promising COVID vaccine maker has struggled mightily; it was late to getting a vaccine approved and to